Pliant Therapeutics Inc

NASDAQ:PLRXUnited States

Pliant Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Its lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The Company has initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF. It has also developed PLN-1474, a small molecule, selective inhibitor of αvß1 integrin for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. It has initiated a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. The Company has a preclinical program, PLN-101325, targeting muscular dystrophies.

Contact Information

Headquarters

260 Littlefield Avenue, Suite 150SOUTH SAN FRANCISCO, CA, United States 94080

Phone

650-481-6770

Fax

---

Executives

Non-Executive Chairman of the Board, Lead Independent Director

Hoyoung Huh

President, Chief Executive Officer, Director

Bernard Coulie

Chief Financial Officer

Keith Cummings

Chief Human Resource Officer

Lily Cheung

General Counsel, Corporate Secretary

Mike Ouimette